{'fraction_non_alphanumeric': 0.02434077079107505, 'fraction_numerical': 0.004056795131845842, 'mean_word_length': 5.877266387726639, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Dynamic DNA methylation discovered during HSC differentiation

Methylation of DNA at CpG dinucleotides is dynamic at many genomic loci during normal development. The continuously differentiating hematopoietic system offers a wellcharacterized model to study these changes in the adult. During normal hematopoietic differentiation, DNA methylation levels have been shown to both increase and decrease as hematopoietic stem cell (HSC) lineage specification progresses. Recent studies of DNA methylation in hematopoietic stem and progenitor (HSPC) populations have elucidated finely tuned methylation changes taking place during differentiation, as well as identified some of the key regulators and drivers of this epigenetic process. Major questions remain, however, regarding the relationship between DNA methylation status, including location in the genome (intron, exon, promoter, intergenic, etc.), and the resultant effect on overall gene expression. Following up on their recent generation and analysis of DNA methylomes in murine HSCs and 4 closely related multipotent progenitor populations (MPPs) using tagmentation-based whole genome bisulfite sequencing (TWGBS), Lipka et al. further categorize the molecular landscape changes in HSPCs during the very early stages of HSC differentiation. They found a number of epigenetic changes that were inversely correlated with gene expression during HSPC differentiation (Fig. 1). During the HSC to MPP1 transition, for example, genes known to be important for normal HSC function, such as Gata2, exhibited increased DNA methylation and decreased gene expression. Across the genome, they identified nearly 16 thousand differentially methylated regions (DMRs), distinguishing several distinct clusters of methylation dynamics. Importantly, the TWGBS approach enabled two-to-three times as many DMRs to be identified as in previous reports of hematopoietic differentiation and better correlation with gene expression changes. Previous studies of DNA methylation during HSPC differentiation used reduced representation bisulfite sequencing (RRBS) or comprehensive highthroughput array-based relative methylation (CHARM) arrays, and a general correlation between DNA methylation levels and gene expression was not observed. In the current study, the majority of DMRs (85%) were exclusively identified by TWGBS, and were found within intragenic regions (57%), which were more likely to be missed by other assays due to an overrepresentation of CpG-rich genomic regions. Lipka et al. also identify a group of 264 “core-enriched” genes, which exhibited an inverse relationship between DNA methylation and gene expression during the HSC to MPP1 transition, but their functional significance remains to be determined. The newly identified DMRs were further analyzed for overlap with regulatory regions associated with hematopoietic-specific transcription factors (TFs); each differentiation stage produced examples of DMRs associated with differentially expressed hematopoietic-specific TFs. The authors propose some of these stage-specific DMRs represent novel cis-acting regulatory regions of TFs important for hematopoietic differentiation, but this will require experimental validation. In addition, probing the DMRs for the presence of canonical TF binding motifs revealed potential involvement of about 30 TFs. The binding site enrichments for specific TF groups were, in turn, limited to specific DMR clusters, possibly implicating a more distinctive, active role for DNA methylation in regulating TF binding in early hematopoiesis. The regulation of, and downstream effects of, DNA methylation changes in the hematopoietic system are crucial to elucidate because a main driver of DNA methylation in HSCs, DNA methyltransferase 3a (DNMT3A), both directly regulates DNA methylation levels in HSCs, and is recurrently mutated in hematologic malignancies, including acute myeloid leukemia. The connection between regulation of DNA methylation in HSCs and development of cancer is still largely unknown, but understanding the epigenetic mechanisms governing differentiation, and the downstream cellular impacts, could provide a great deal of insight. Overall, this study provides important insights into DNA methylation dynamics of early HSC differentiation, and a roadmap for experimental exploration of potential downstream effects of epigenetic aberrations, such as DNMT3A mutations, in hematologic malignancy and disease. Many important questions remain for the future. For example, the functional relevance of the 9 DMR clusters, particularly given the enrichment of specific TF binding motifs, is intriguing. As the authors suggest, genomewide mapping of protein binding via chromatin-Immunoprecipitation sequencing (ChIP-Seq) will be required to address this question, as well as determining the effect of DNA methylation dynamics on TF binding. It would additionally be useful to